These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34554232)

  • 1. Impact of teleconsultation on subsequent disease activity and flares in patients with systemic lupus erythematosus.
    Au Eong JTW; Lateef A; Liang S; Lim SHH; Tay SH; Mak A; Cho J
    Rheumatology (Oxford); 2022 May; 61(5):1911-1918. PubMed ID: 34554232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
    Thanou A; Chakravarty E; James JA; Merrill JT
    Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
    Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting flares in patients with stable systemic lupus erythematosus.
    Cho J; Lahiri M; Teoh LK; Dhanasekaran P; Cheung PP; Lateef A
    Semin Arthritis Rheum; 2019 Aug; 49(1):91-97. PubMed ID: 30660381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flares in pediatric systemic lupus erythematosus.
    Weiss JE; Sison CP; Ilowite NT; Gottlieb BS; Eberhard BA
    J Rheumatol; 2007 Jun; 34(6):1341-4. PubMed ID: 17477466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio reflect disease activity and flares in patients with systemic lupus erythematosus - A prospective study.
    Cho J; Liang S; Lim SHH; Lateef A; Tay SH; Mak A
    Joint Bone Spine; 2022 Jul; 89(4):105342. PubMed ID: 35032639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study.
    Saraiva L; Cunha RN; Jesus D; Gatto M; Zen M; Iaccarino L; da Silva JAP; Doria A; Inês LS
    Rheumatology (Oxford); 2024 Apr; 63(4):1123-1129. PubMed ID: 37458482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study.
    Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R
    Lupus; 2021 Sep; 30(10):1586-1595. PubMed ID: 34192957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
    Zen M; Bassi N; Nalotto L; Canova M; Bettio S; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
    Clin Exp Rheumatol; 2012; 30(6):856-63. PubMed ID: 22765883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
    Mok CC; Ying SK; Ma KM; Wong CK
    Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
    Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A
    Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of specialty care in the management of patients with systemic lupus erythematosus.
    Urowitz MB; Kagal A; Rahman P; Gladman DD
    J Rheumatol; 2002 Jun; 29(6):1207-10. PubMed ID: 12064836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study.
    Peng L; Wang Z; Li M; Wang Y; Xu D; Wang Q; Zhang S; Zhao J; Tian X; Zeng X
    Clin Rheumatol; 2017 Dec; 36(12):2727-2732. PubMed ID: 28929239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort.
    Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Medina M; Elera-Fitzcarrald C; Zevallos F; Pastor-Asurza CA; Zazzetti F; Karyekar CS; Alarcón GS; Perich-Campos RA
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35351811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.
    Inês L; Duarte C; Silva RS; Teixeira AS; Fonseca FP; da Silva JA
    Rheumatology (Oxford); 2014 Jan; 53(1):85-9. PubMed ID: 24067885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
    Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB
    J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.